Log in to search using one of your social media accounts:


Labmade smallpox is possible, study shows

Source: ScienceNOW - Category: Science Authors: Tags: Pharmacology, Toxicology, Science and Policy, Virology In Depth Source Type: news

Related Links:

(Natural News) A team of researchers at the University of Alberta in Canada have successfully recreated a virus known as horsepox, which contains similar characteristics as smallpox. According to the research team, the goal of the process was to improve the current techniques in vaccine development and improve public safety. However, the researchers did not disclose how they...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
US-based Emergent BioSolutions has entered an agreement to buy the ACAM2000, smallpox vaccine business of French pharmaceutical company Sanofi for up to $125m.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
Researchers from the University of Alberta have resurrected a virus called horsepox, which is very similar to smallpox (artist's impression pictured inset).
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
World Health Organization. 05/2017 This 58-page report summarizes the 18th meeting of the Advisory Committee on Variola Virus Research, held on November 2-3, 2016. The Advisory Committee reviewed the implications for its upcoming work in light of the 69th World Health Assembly's decision to have a substantive agenda item at the 72nd World Health Assembly in May 2019 on the destruction of smallpox virus stocks. It was also updated on continuing research projects using live variola virus for the development of diagnostic tests, animal models, smallpox vaccines, and antiviral and therapeutic agents. (PDF)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Authors: Source Type: news
World Health Organization. 10/2016 This 10-page report summarizes an inspection carried out at the World Health Organization-authorized variola virus (smallpox)repository at the Centers for Disease Control and Prevention (CDC) in May 2015. It included inspection of the physical high-containment facilities designated for research use of variola virus, the supporting engineering systems, and the long-term secure specimen storage arrangement. The team heard presentations from and had interactive discussions with CDC staff and reviewed records, regulatory instruments, instruction manuals, meeting minutes, floor plans, and othe...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Authors: Source Type: news
National Institutes of Health. 05/2017 This 50-page document is the report of the National Institutes of Health (NIH) Blue Ribbon Panel appointed to review the July 2014 discovery of six vials containing variola virus, the causative agent of smallpox, as well as over 300 other previously undiscovered biological samples on the NIH Bethesda, MD, campus. The panel identified several key factors that contributed to the smallpox virus incident, and noted several specific problematic issues relating to the immediate response after discovery of the smallpox virus and other samples. (PDF)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Authors: Source Type: news
U.S. Food and Drug Administration. 12/13/2016 This nine-page report provides information about the discovery of vials labeled as Variola (the virus that causes smallpox) during cleanup and inventory on July 1, 2014, in preparation for a move of the Food and Drug Administrations (FDA) laboratories located at the National Institutes of Health (NIH) campus in Bethesda, MD, to FDA's White Oak campus in Silver Spring, MD. It reflects interviews with FDA and NIH employees associated with the cold storage room in which the vials were discovered, a site visit to the NIH campus, and a thorough review of all available reports and do...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Authors: Source Type: news
Biological threats pose some of the gravest health risks in our increasingly interconnected world. They can be naturally occurring, such as outbreaks of Ebola infections, or bioterrorism, such as the anthrax attacks in 2001. A study reported this week renews worries about human-made biological agents. Scientists synthesized an extinct horsepox virus closely related to smallpox, the deadliest microbe in human […]Related:Trump administration names Georgia health official as new CDC directorDeaths from cancer higher in rural America, CDC findsHer newborn kept getting sick because she was ingest...
Source: Washington Post: To Your Health - Category: Consumer Health News Source Type: news
Authors: Alvarez C, Tapia T, Perez-Moreno E, Gajardo-Meneses P, Ruiz C, Rios M, Missarelli C, Silva M, Cruz A, Matamala L, Carvajal-Carmona L, Camus M, Carvallo P Abstract Identifying founder mutations in BRCA1 and BRCA2 in specific populations constitute a valuable opportunity for genetic screening. Several studies from different populations have reported recurrent and/or founder mutations representing a relevant proportion of BRCA mutation carriers. In Latin America, only few founder mutations have been described. We screened 453 Chilean patients with hereditary breast cancer for mutations in BRCA1 and BRCA2. For...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Aethlon Medical (NSDQ:AEMD) said today it is submitting an expedited access pathway application to the FDA seeking a breakthrough technology designation for its hemopurifier. Aethlon’s Hemopurifier device is a single-use, disposable cartridge designed to target and filter out viruses or tumor-secreted exosomes. Blood flows through the cartridge into nearly 3,000 hollow fibers with pores 250 nanometers in diameter. A pressure deferential in the 1st third of the fiber pushes particles below 250 nanometers through the pores into a space between the fibers and the cartridge. The San Diego, Calif.-based com...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blood Management Regulatory/Compliance Aethlon Medical Inc. Source Type: news
More News: Drugs & Pharmacology | Science | Smallpox | Study | Toxicology | Virology